TY - JOUR
T1 - Characteristics and clinical outcomes of patients with pre-delta, delta and omicron SARS-CoV-2 infection in Indonesia (2020–2023)
T2 - a multicentre prospective cohort study
AU - Karuniawati, Anis
AU - Pasaribu, Ayodhia Pitaloka
AU - Lazarus, Gilbert
AU - Irawany, Vera
AU - Nusantara, Dwi Utomo
AU - Sinto, Robert
AU - Suwarti, null
AU - Nasution, Maulana Jamil
AU - Ferawati, null
AU - Lubis, Muhammad Riza
AU - Nurfitri, Eka
AU - Mutiara, Mutiara
AU - Arifin, Hasanul
AU - Hely, Hely
AU - Putri, Pramaisshela Arinda D.
AU - Pradipta, Ariel
AU - Susanto, Anindya Pradipta
AU - Kumaheri, Meutia Ayuputeri
AU - Bonifacius, null
AU - Da Costa, Yacobus
AU - Bogh, Claus
AU - Safari, Dodi
AU - Lidia, Kartini
AU - Malewa, Hermi Indita
AU - Nuraeni, Nunung
AU - Zanjabila, Sabighoh
AU - Rahardjani, Mutia
AU - Dewi, Fitri Agustia
AU - Wulandari, Fitria
AU - Subekti, Decy
AU - Surendra, Henry
AU - Baird, J. Kevin
AU - Shankar, Anuraj H.
AU - Hamers, Raph L.
N1 - Funding Information:
University of Oxford and Wellcome Trust.
Publisher Copyright:
© 2023
PY - 2024/3
Y1 - 2024/3
N2 - Background: Limited data exist from southeast Asia on the impact of SARS-CoV-2 variants and inactivated vaccines on disease severity and death among patients hospitalised with COVID-19. Methods: A multicentre hospital-based prospective cohort was enrolled from September 2020 through January 2023, spanning pre-delta, delta, and omicron periods. The participant hospitals were conveniently sampled based on existing collaborations, site willingness and available study resources, and included six urban and two rural general hospitals from East Nusa Tenggara, Jakarta, and North Sumatra provinces. Factors associated with severe disease and day-28 mortality were examined using logistic and Cox regression. Findings: Among 822 participants, the age-adjusted percentage of severe disease was 26.8% (95% CI 22.7–30.9) for pre-delta, 50.1% (44.0–56.2) for delta, and 15.2% (9.7–20.7) for omicron. The odds of severe disease were 64% (18–84%) lower for omicron than delta (p < 0.001). One or more vaccine doses reduced the odds of severe disease by 89% (65–97%) for delta and 98% (91–100%) for omicron. Age-adjusted mortality was 11.9% (8.8–15.0) for pre-delta, 24.4% (18.8–29.9) for delta and 9.6% (5.2–14.0) for omicron. The day-28 cumulative incidence of death was lower for omicron (9.2% [5.6–13.9%]) than delta (28.6% [22.0–35.5%]) (p < 0.001). Severe disease on admission was the predominant prognostic factor for death (aHR34.0 [16.6–69.9] vs mild-or-moderate; p < 0.001). After controlling for disease severity on admission as an intermediate, the risk of death was 48% (32–60%) lower for omicron than delta (p < 0.001); and 51% (38–61%; p < 0.001) lower for vaccinated participants than unvaccinated participants overall, and 56% (37–69%; p < 0.001) for omicron, 46% (−5 to 73%; p = 0.070) for pre-delta (not estimable for delta). Interpretation: Infections by omicron variant resulted in less severe and fatal outcomes than delta in hospitalised patients in Indonesia. However, older, and unvaccinated individuals remained at greater risk of adverse outcomes. Funding: University of Oxford and Wellcome Trust.
AB - Background: Limited data exist from southeast Asia on the impact of SARS-CoV-2 variants and inactivated vaccines on disease severity and death among patients hospitalised with COVID-19. Methods: A multicentre hospital-based prospective cohort was enrolled from September 2020 through January 2023, spanning pre-delta, delta, and omicron periods. The participant hospitals were conveniently sampled based on existing collaborations, site willingness and available study resources, and included six urban and two rural general hospitals from East Nusa Tenggara, Jakarta, and North Sumatra provinces. Factors associated with severe disease and day-28 mortality were examined using logistic and Cox regression. Findings: Among 822 participants, the age-adjusted percentage of severe disease was 26.8% (95% CI 22.7–30.9) for pre-delta, 50.1% (44.0–56.2) for delta, and 15.2% (9.7–20.7) for omicron. The odds of severe disease were 64% (18–84%) lower for omicron than delta (p < 0.001). One or more vaccine doses reduced the odds of severe disease by 89% (65–97%) for delta and 98% (91–100%) for omicron. Age-adjusted mortality was 11.9% (8.8–15.0) for pre-delta, 24.4% (18.8–29.9) for delta and 9.6% (5.2–14.0) for omicron. The day-28 cumulative incidence of death was lower for omicron (9.2% [5.6–13.9%]) than delta (28.6% [22.0–35.5%]) (p < 0.001). Severe disease on admission was the predominant prognostic factor for death (aHR34.0 [16.6–69.9] vs mild-or-moderate; p < 0.001). After controlling for disease severity on admission as an intermediate, the risk of death was 48% (32–60%) lower for omicron than delta (p < 0.001); and 51% (38–61%; p < 0.001) lower for vaccinated participants than unvaccinated participants overall, and 56% (37–69%; p < 0.001) for omicron, 46% (−5 to 73%; p = 0.070) for pre-delta (not estimable for delta). Interpretation: Infections by omicron variant resulted in less severe and fatal outcomes than delta in hospitalised patients in Indonesia. However, older, and unvaccinated individuals remained at greater risk of adverse outcomes. Funding: University of Oxford and Wellcome Trust.
KW - COVID-19
KW - Disease severity
KW - Inactivated vaccine
KW - Indonesia
KW - Mortality
KW - Prospective study
KW - SARS-CoV-2 variants of concern
UR - https://www.scopus.com/pages/publications/85183650276
U2 - 10.1016/j.lansea.2023.100348
DO - 10.1016/j.lansea.2023.100348
M3 - Article
C2 - 38482150
AN - SCOPUS:85183650276
SN - 2772-3682
VL - 22
JO - The Lancet Regional Health - Southeast Asia
JF - The Lancet Regional Health - Southeast Asia
M1 - 100348
ER -